Posted 22nd October 2018 by Kate Barlow
The Probiotics/Prebiotics Market
Interest in microbiota, specifically in human health and disease, has encouraged consumers to focus on digestive health, which has seen the probiotics and prebiotics market go from strength-to-strength.
As a result, the global probiotics and prebiotics market was valued at approximately USD 40.09 billion in 2017 and is expected to generate revenue of around USD 65.87 billion by end of 2024, growing at a compound annual growth rate of around 7.35% between 2018 and 2024. 
Posted 13th December 2017 by Laura Berry
A prebiotic is defined as “a substrate that is selectively utilised by host microorganisms conferring a health benefit”. This updated consensus definition from the International Scientific Association for Probiotics and Prebiotics expands the application outside the digestive tract.
Posted 4th October 2017 by Laura Berry
Interest in microbiota has reached all areas of human health and disease. As a result, the therapeutic potential of probiotics has expanded. 2013 saw a surge of investment into prebiotics and probiotics, coinciding with an increase in microbiome funding. In the last decade, investment has quadrupled.
Posted 17th March 2017 by Laura Berry
Edible fungi or mushrooms are widely used as healthy food and nutraceutical products due to their high nutritive and medicinal value. The world production and consumption of edible and medicinal mushrooms has experienced a steady increase over the last few decades (>25-fold increase in 35 years from 1978 – 2012) and is projected to grow at 9.5% annually from 2014 to 2019, tripling the world GDP growth from 2013 – 2018 (2.5 – 3.0%).
Posted 10th March 2017 by Laura Berry
Physical, chemical and biological stresses are the order of the day for cultured fish. The expansion of aquaculture over the last three decades to complement capture fisheries means that farmers are increasing stocking densities and feed input per production unit.
Posted 11th July 2018 by Kate Barlow
This article was originally published in Health Europa Quarterly on 3 May 2018, and is published here with permission.
Johan van Hylckama Vlieg is the vice-president for microbiome and human health innovation at Chr. Hansen A/S, a global leading bioscience company that develops and produces cultures, enzymes, probiotics and natural colours for the food, nutritional, pharmaceutical and agricultural industries.
Speaking at the 5th Microbiome R&D & Business Collaboration Forum: Europe, van Hylckama Vlieg provided a valuable insight into some of the exciting potential application areas of probiotics.